Indian drugmaker Cipla Ltd will price generic adaptation of Gilead Sciences Inc's antiviral medication remdesivir for use in COVID-19 patients at under 5,000 rupees ($66), the organization said.
Cipla and privately held Indian drugmaker Hetero Labs on Sunday picked up endorsement to sell generic variants of remdesivir in the nation. Hetero hopes to value a comparable 100-milligram dose of the treatment at 5,000 to 6,000 rupees.
Beximco Pharmaceuticals Ltd, one of Bangladesh's biggest drugmakers, in May turned into the first organization in the world to present a branded version of remdesivir. Cipla only announced that the organization was wanting to price its COVID-19 Tablet between 5,000 to 6,000 takas ($59 to $71) per vial.
Cipla, in an email statement, mentioned about the tablet and its price range but did not mention when the tablet will be available.